Blood Cancer United (Formerly Reported Asthe Leukemia and Lymphoma Society)
Non profit dedicated to funding blood cancer research.
Based in DC
🤖
AI Overview
With $1.5M in lobbying spend across 30 quarterly filings, Blood Cancer United (Formerly Reported Asthe Leukemia and Lymphoma Society) is a significant lobbying presence.
$1.5M
Total Lobbying Spend
30
Quarterly Filings
1
Lobbying Firms Used
7
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $200K |
| 2019 | $350K |
| 2020 | $100K |
| 2021 | $150K |
| 2022 | $200K |
| 2023 | $200K |
| 2024 | $160K |
| 2025 | $180K |
Lobbying Firms
KOUNTOUPES DENHAM CARR & REID, LLC
What They Lobby For
- Issues related to Medicare Part D as related to blood cancer beneficiaries.
- Issues related to the cost of care and protecting patient access to blood cancer treatment. Issues related to specialty drug tiers.
- Issues related to blood cancer research funding included in H. R. 1625, the Consolidated Appropriations Act of 2018.
- Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act. Issues related to "right-to-try" legislation, including H. R. 878 and S.204 the Right to Try Act of 2017.
- Issues related to blood cancer research funding included in the FY 2019 Labor-HHS and Department of Defense Appropriations Bills.
- Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act. Issues related to "right-to-try" legislation, including H. R. 878 and S.204 the Right to Try Act of 2017. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
- Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R.1409 the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer, including H. R. 820, the Childhood Cancer STAR Act, and it's Senate companion S.292, the Childhood Cancer Survivorship, Treatment Access, and Research Act of 2018. Issues related to Health Savings Accounts. Issues related to Short-Term Limited Duration health insurance plans.
- Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1409, the Cancer Drug Parity Act of 2017. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
- Issues related to blood cancer research funding included in the FY 2020 Labor-HHS and Department of Defense Appropriations Bills.
- Issues related to blood cancer research, diagnosis, treatment and cures including coverage and reimbursement of cancer treatment therapies and issues related to H. R. 1730/S.741, the Cancer Drug Parity Act of 2019. Issues related to patient protections for blood cancer patients. Issues related to insurance market stabilization. Issues related to pediatric cancer.
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.